Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Adaptive Biotechnologies Corporation, 3 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Adaptive Biotechnologies Corporation | Option exercise | +52,084 | $7.80 | $406,255 |
| Jun 25, 2026 | Adaptive Biotechnologies Corporation | Open-market sale | −52,084 | $20.18 | $1,051,055 |
| Mar 11, 2026 | Adaptive Biotechnologies Corporation | Open-market sale | −15,394 | $13.91 | $214,131 |
| Mar 4, 2026 | Adaptive Biotechnologies Corporation | Grant or award | +15,625 | — | — |
| Mar 3, 2026 | Adaptive Biotechnologies Corporation | Option exercise | +48,044 | $3.99 | $191,696 |
| Mar 3, 2026 | Adaptive Biotechnologies Corporation | Open-market sale | −48,044 | $15.30 | $735,073 |
| Mar 13, 2025 | Adaptive Biotechnologies Corporation | Open-market sale | −36,291 | $7.19 | $260,932 |
| Mar 6, 2025 | Adaptive Biotechnologies Corporation | Open-market sale | −15,664 | $7.94 | $124,372 |
| Mar 4, 2025 | Adaptive Biotechnologies Corporation | Grant or award | +15,394 | — | — |
| Mar 4, 2024 | Adaptive Biotechnologies Corporation | Grant or award | +31,328 | — | — |
| Mar 27, 2023 | Adaptive Biotechnologies Corporation | Open-market sale | −2,341 | $8.49 | $19,875 |
| Mar 6, 2023 | Adaptive Biotechnologies Corporation | Grant or award | +14,775 | — | — |
Questions about Michelle Renee Griffin
What boards is Michelle Renee Griffin on?
Michelle Renee Griffin sits on the board of Adaptive Biotechnologies Corporation.
How long has Michelle Renee Griffin served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.